There aren’t many S&P/ASX 200 Index (ASX: XJO) shares that have been hit harder than WiseTech Global Ltd (ASX: WTC).

The WiseTech share price is currently trading around $33 a pop, leaving it down almost 20% over the past month.

Zoom out further, and things look much worse, with the logistics software company’s shares losing more than 60% over the past 12 months.

But at these levels, I think the market has gone too far.

In fact, I believe WiseTech is now one of the most undervalued growth stocks on the ASX 200.

And I’m becoming increasingly bullish on where its shares could go from here.

Look beyond the share price

It’s easy to look at WiseTech’s chart and assume something has gone seriously wrong with the business.

But its FY26 numbers tell a very different story.

Revenue jumped 79% to US$1.396 billion, while underlying EBITDA increased 56% to US$644.5 million.

CargoWise remains the part of the business that excites me most.

Revenue from the platform increased 11% to US$756.9 million in FY26, while customer attrition remains extremely low.

WiseTech also has more large global freight forwarders moving onto CargoWise, giving the company another long runway for growth.

That makes the current valuation much more interesting to me than it was when the shares were trading above $100.

The next chapter could be much bigger

But I don’t think investors should value WiseTech purely on what it earned last year.

The acquisition of e2open has dramatically increased the company’s size and created another major opportunity to improve margins.

WiseTech has already been cutting costs across the combined business, while its growing use of AI could drive further efficiencies.

The company is targeting FY27 revenue of US$1.48 billion to US$1.54 billion and underlying EBITDA of US$725 million to US$780 million.

That implies underlying EBITDA growth of roughly 12% to 21%, with margins expected to reach 49% to 51%.

Meanwhile, leverage is expected to fall to around 2.2 times by the end of FY27 and below 2 times in FY28.

Put those pieces together, and I think WiseTech could emerge from this period as a considerably larger and more profitable business.

Would I buy WiseTech shares?

Absolutely.

The market is currently treating WiseTech like its best days are behind it.

I think the opposite could prove true.

CargoWise remains an outstanding global software platform, and margins have plenty of room to improve.

Yes, there are risks, particularly around integrating e2open and delivering its FY27 targets.

But with WiseTech shares around $33, I’m more interested in the potential reward.

I think this sell-off has created one of the most attractive growth opportunities on the ASX 200.

The post Is WiseTech the most undervalued growth stock on the ASX 200? appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares set to soar 39% to 135%
• Want to retire early? Here’s where I’d put my money
• 5 best ASX shares to buy in October
• These 3 ASX 200 shares have lost 49%+ in 2026. Are any now bargains?
• Should I invest $5,000 into WiseTech and Xero shares?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL vs Pro Medicus shares: Which ASX healthcare stock should you buy in October?

When Aussie investors think “healthcare blue-chip”, CSL Ltd (ASX: CSL) probably springs to mind. But rapid-growing tech player Pro Medicus Ltd (ASX: PME) is making waves of its own. Both operate in the fast-evolving healthcare sector, but their businesses, fundamentals and shares shape up very differently. With October upon us, here’s how CSL and Pro Medicus compare for investment appeal right now.

The case for CSL

CSL is a long-established giant in global biotherapy and vaccine development, with more than a century under its belt. Its core business sprawls from treating rare diseases and producing vaccines, through to iron deficiency and kidney health, with operations in over 40 countries. CSL’s key divisions include CSL Behring (plasma therapies), Seqirus (vaccines), and Vifor (nephrology), making it a highly diversified healthcare operator.

Looking at the numbers, CSL boasts a massive $87.3 billion market cap, cementing its blue-chip status on the ASX. Its price/earnings (P/E) ratio sits at 18.12, considerably lower than many growth-focused healthcare peers. A dividend yield of 2.29% and a payout of $4.05 per share will appeal to income-minded investors, though notably, its dividends are currently unfranked. For 2026 to date, the shares have delivered a positive return of 4.8%.

Interestingly, CSL’s reported earnings per share (EPS) in this snapshot is negative (-5.35), which doesn’t mathematically square with a positive P/E ratio. Note: CSL’s reported P/E ratio may be based on a different earnings measure (e.g. underlying or forward earnings) than the EPS figure shown, which is why they may appear inconsistent.

The case for Pro Medicus

Pro Medicus is a healthcare technology company specialising in medical imaging software used by radiology clinics and hospitals. Its main products — advanced Radiology Information Systems (RIS) and Picture Archiving and Communication Systems (PACS) — help streamline image management and reporting for some of the world’s top medical centres, especially in the US. The company also offers workflow optimisation, network design, and training.

While much younger and nimbler than CSL, Pro Medicus has grown into a $16.94 billion company as of the latest data snapshot. Its valuation is rich: a P/E ratio of 63.49 reflects the high growth investors expect from healthcare tech disruptors. For dividend hunters, Pro Medicus pays out a much smaller (but fully franked) yield of 0.43%, with a dividend of $0.69 per share.

Notably, Pro Medicus has posted positive EPS (2.536), but its shares have struggled this year, dropping -26.8% year to date. That underperformance stands in sharp contrast to CSL’s modest gains.

Valuation comparison

Here’s how CSL and Pro Medicus compare on fundamentals, using the latest available numbers:

Metric	CSL	Pro Medicus
Market Cap	$87.30 billion	$16.94 billion
P/E Ratio	18.12	63.49
Dividend Yield	2.29% (Unfranked)	0.43% (100% Franked)
Dividend per Share	$4.05	$0.69
Year To Date Return	4.8%	-26.8%
Earnings per Share	-5.350	2.536

Note: CSL’s positive P/E and negative EPS figures may seem inconsistent; this could be because underlying or forward earnings have been used for the P/E.

Recent share price performance

Comparing recent share price action up to 28 September, here’s how their shares moved heading into October:

• As of 28 Sep 2026, CSL shares closed at $181.91, gaining 2.8% on the day and advancing 4.8% year to date.
• As of 28 Sep 2026, Pro Medicus shares ended at $162.15, rising 0.7% for the day but down sharply, by -26.8% year to date.

So while CSL has trended higher in 2026 so far, Pro Medicus has seen a notable pullback despite its earlier strong run.

Which is the better buy?

If I had to choose just one ASX healthcare share for October, my pick would be CSL. Here’s why: Despite a challenging couple of years, CSL offers the steadiness of a global leader with a long track record, a mid-range (for healthcare) P/E ratio, and a solid dividend yield — all with demonstrated year-to-date gains. Its scale, diversification, and staying power make it hard to look past, even allowing for some confusion around current reported earnings.

Pro Medicus is an exciting disruptor with unique tech and exposure to US healthcare, but its lofty valuation (P/E above 60) and steep share price slide this year make it tougher for me to justify at current prices. While Pro Medicus’ 100% franking is a perk, its yield is modest and its short-term momentum is firmly negative.

For a mix of quality, income and market resilience in the current environment, I think CSL stands out as the better buy for October.

The post CSL vs Pro Medicus: Which ASX healthcare share is better? appeared first on The Motley Fool Australia.

More reading

• 5 leading ASX shares I’d buy and hold until 2040
• Expert names Woodside and CSL shares as top buys today
• What would it take for CSL shares to return to $250?
• Buy, hold, sell: Fortescue, Westpac, CSL shares
• Experts name 3 popular ASX 200 shares to buy this week

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Holding an ASX share until 2040 is a big commitment.

For me, that means looking for businesses with strong competitive positions, long growth runways, and products or services that should still be relevant many years from now.

These are five leading ASX shares I would be comfortable buying with that timeframe in mind.

Pro Medicus Ltd (ASX: PME)

Pro Medicus would be one of my first choices. Its Visage imaging software is used by major healthcare organisations to manage and view increasingly large volumes of medical imaging data.

What I like is the combination of a highly scalable software model and exposure to a healthcare system that continues to generate more imaging.

The technology company has also shown it can win large customers in the United States, giving it plenty of room to keep expanding internationally.

By 2040, I think medical imaging will be even more digital, data-heavy, and AI-assisted than it is today. Pro Medicus looks well placed to grow alongside that shift.

Commonwealth Bank of Australia (ASX: CBA)

CBA brings a very different type of strength.

It is already Australia’s largest bank, with leading positions across home lending, deposits, and digital banking.

That means I would not expect explosive growth over the next 14 years. The attraction here is the quality and resilience of the franchise.

Banking should remain a core part of the Australian economy for decades, and I think CBA’s scale, customer base, and technology investment leave it well positioned to keep earning attractive returns.

For me, that makes it the major bank I would be most comfortable owning through multiple economic cycles.

Cochlear Ltd (ASX: COH)

Cochlear is another ASX share I think suits a very long investment horizon.

The company is a global leader in implantable hearing solutions, helping people with severe hearing loss regain access to sound.

Ageing populations and greater awareness of hearing loss could continue to increase demand over time, while ongoing innovation should broaden the range of patients who can benefit from treatment.

I also like that Cochlear operates in a specialised medical field where clinical expertise, technology, and trusted relationships with healthcare professionals are difficult to replicate.

That gives me confidence in its ability to remain relevant well beyond the next few years.

Xero Ltd (ASX: XRO)

Xero would provide the portfolio with long-term technology exposure.

Its accounting platform is deeply integrated into the day-to-day operations of small businesses, accountants, and bookkeepers across the world.

However, with a total addressable market estimated to be around 100 million businesses globally, Xero is still only scratching the surface of its market opportunity with its 4.9 million customers.

If the company can keep growing its market share, I think it could be a much larger business by 2040.

NextDC Ltd (ASX: NXT)

This ASX share rounds out my five.

NextDC develops and operates data centres, giving investors direct exposure to the enormous growth in digital infrastructure.

Cloud computing was already driving demand before the current AI boom. Artificial intelligence is adding another layer because training and running increasingly powerful models requires huge amounts of computing capacity.

That creates demand for secure facilities with access to power, connectivity, and large amounts of technical infrastructure.

NextDC still has plenty to execute as it expands its capacity, but I think the structural demand behind the business could run for many years.

Foolish takeaway

A lot can change between now and 2040, so I would not expect every year to be smooth for any of these businesses.

What gives me confidence is that each one is exposed to a long-term need I can still see as important well into the future, whether that is healthcare, banking, small-business software, or digital infrastructure.

That is the sort of foundation I would want before committing to holding an ASX share for the next 14 years.

The post 5 leading ASX shares I’d buy and hold until 2040 appeared first on The Motley Fool Australia.

More reading

• Commonwealth Bank vs ANZ: Which is better for passive income?
• Sell alert! Expert calls time on Corporate Travel and CBA shares
• Buy, hold, sell: Premier Investments, New Hope, Xero shares
• Can the Xero share price climb back to $100?
• ASX 200 holds steady as investors brace for a big afternoon

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Cochlear and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.